Roles and potential therapeutic targets of the ubiquitin proteasome system in muscle wasting

BMC Biochem. 2007 Nov 22;8 Suppl 1(Suppl 1):S7. doi: 10.1186/1471-2091-8-S1-S7.

Abstract

Muscle wasting, characterized by the loss of protein mass in myofibers, is in most cases largely due to the activation of intracellular protein degradation by the ubiquitin proteasome system (UPS). During the last decade, mechanisms contributing to this activation have been unraveled and key mediators of this process identified. Even though much remains to be understood, the available information already suggests screens for new compounds inhibiting these mechanisms and highlights the potential for pharmaceutical drugs able to treat muscle wasting when it becomes deleterious. This review presents an overview of the main pathways contributing to UPS activation in muscle and describes the present state of efforts made to develop new strategies aimed at blocking or slowing muscle wasting. Publication history: Republished from Current BioData's Targeted Proteins database (TPdb; http://www.targetedproteinsdb.com).

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Drug Delivery Systems / methods*
  • Drug Delivery Systems / trends
  • Enzyme Inhibitors / pharmacology
  • Enzyme Inhibitors / therapeutic use
  • Humans
  • Muscular Atrophy / drug therapy
  • Muscular Atrophy / enzymology*
  • Proteasome Endopeptidase Complex / metabolism*
  • Proteasome Inhibitors
  • Ubiquitin-Protein Ligase Complexes / antagonists & inhibitors
  • Ubiquitin-Protein Ligase Complexes / metabolism*

Substances

  • Enzyme Inhibitors
  • Proteasome Inhibitors
  • Ubiquitin-Protein Ligase Complexes
  • Proteasome Endopeptidase Complex